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Key-points (max5): 
 Case only designs support the association between antidepressant use 
and hip fracture in electronic healthcare databases in accordance with 
results from traditional designs (cohort and nested case-control).  
 In this study assumptions of the case-crossover design are violated with 
regard to exchangeability and length of exposure and transient effects on 
outcome.  
 The self-controlled case-series seems to be an appropriate design for 
assessing the association between antidepressant use and hip fracture. 
Moreover, it shows a similar risk estimate for SSRI and TCA in contrast to 
case-crossover, nested case-control and cohort. 
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Abstract (max 250) 246 
 
Purpose: To evaluate the performance and validity of the case-crossover (CCO) 
and self-controlled case-series (SCCS) designs when studying the association 
between hip/femur fracture (HF) and antidepressant (AD) use in general 
practitioner databases. In addition, comparability to cohort and case-control 
designs is discussed. 
Methods: Adult patients with HF and who received an AD prescription during 
2001-2009 were identified from UK THIN and the Dutch Mondriaan databases. 
AD exposure was classified into current, recent, and past/non-use (reference). In 
the CCO, for each patient, a case moment (date of HF) and four prior control 
moments at -91, -182, -273, and -365 days were defined. In SCCS, incidence of HF 
was compared between exposure states. Conditional logistic regression was used 
in the CCO and Poisson regression in the SCCS to compute odds ratios (OR) and 
incidence rate ratios (IRR), respectively. In CCO, we adjusted for time varying co-
medication and in SCCS for age.  
Results: Adjusted estimates for the effect of current AD exposure on HF were 
higher in the CCO (co-medication adjusted OR, THIN: 2.24, 95%CI: 2.04 – 2.47; 
Mondriaan: 2.57, 95%CI: 1.50 - 4.43) than in the SCCS (age-adjusted IRR, THIN: 
1.41, 95%CI:1.32– 1.49; Mondriaan: 2.14, 95%CI:1.51 – 3.03). The latter were 
comparable to the traditional designs. 
Conclusion: Case only designs confirmed the association between AD and HF. 
The CCO design violated assumptions in this study with regard to 
exchangeability and length of exposure, and transient effects on outcome. The 
SCCS seems to be an appropriate design for assessing AD-HF association. 
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Introduction 
Assessing the association between hip or femur fracture (HF) and 
antidepressants (AD) is challenging and dissimilar results have been reported.1, 2 
The risk of HF is influenced by both the strength of the bones and the chance of 
falling. Either of these can be directly or indirectly affected by factors such as 
patient characteristics and the environment. These include age, sex, physical 
fitness, neurological status, nutrition habits, hormonal status, drug use and 
morbidity.3, 4 
Estimation of an association between drug use and HF might be confounded by 
any of these factors, especially when both the indication for the drug and the risk 
of the outcome are related to these factors.5, 6 As long as these factors are 
accurately measured and available in our data we can adjust for them in 
traditional designs like the cohort and case-control.7-9 
Case only designs, where cases serve as their own controls, are not subject to 
bias caused by measured and unmeasured time-invariant confounders such as 
genetics, frailty, or underlying disease. In addition, potential selection bias when 
sampling controls, provided that timing of the control moments is correct, is 
absent. Application of these case-only designs seems therefore attractive, but 
suitability of these designs to study a specific association within the same person 
depends on transience of exposure and outcome and thus requires several 
assumptions related to exposure over time and the time relation with the 
outcome.10 While studying the association between AD use and HF in electronic 
health care databases, we aim 1) to compare the risk estimates of the case-
crossover (CCO)11, 12 to the self-controlled case-series (SCCS) design, 2) assess 
the effects when the assumptions for each of these designs are violated, and 3) to 
compare the results with traditional cohort and (nested) case-control (NCC) 
designs. 13 
 
Methods 
Setting and study population 
A common protocol and data specification for both the case only designs (this 
manuscript) and the traditional methods (described in more detail in this PDS 
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issue 13) were registered with the European Network of Centres for 
Pharmacoepidemiology and Pharmacovigilance (ENCePP). 14  
The association between AD use and HF was assessed using electronic health 
records from the United Kingdom collected by The Health Improvement 
Network (THIN). For a subset of the analyses data from the Mondriaan database 
was used as a second data source to illustrate feasibility and generalizability on a 
small database. The Dutch Mondriaan database combines data extracted from 
the NIVEL Primary Care Research Database and the Almere Health Care Group 
database. These data sources are described in more details elsewhere. 9 A 
blinding procedure was maintained until all results were available at the 
coordinating centre (at Utrecht University, the Netherlands). 
The study period was defined as from 1st January 2001 to 31st December 2009. 
The study population included all patients who met the following criteria: i) ≥ 18 
years old; ii) having had at least one year of enrolment with the GP; iii) received 
at least one AD prescription; iv) had a recorded diagnosis of HF during the study 
period and v) had to have 12 months free of HF before the observation period 
started in order to ensure they experienced ‘new’ events. 
 
Exposure and outcome definition 
The exposure of interest was an AD prescription (ATC N06AA [TCA] or N06AB 
[SSRI]).14 In THIN, AD prescription duration was estimated based on the amount 
prescribed and the dosage regimen. Because this information was unavailable in 
Mondriaan, a fixed duration of 90 days was set for each AD, based on the 
maximal prescription duration for chronic prescriptions in the Netherlands.  
AD treatment episodes were constructed for each patient and exposure time was 
divided into periods of non use, current, recent and past use. 15 Periods of 
‘current use’ were extended with 30 days after the theoretical end date of the 
last prescription within a treatment episode and followed by 60 days of ‘recent 
use’. After that time and until renewal, exposure was defined as ‘past use’ that 
together with ‘non use’ served as reference category (see Figure 1).  
 
HF cases were defined as patients having a code for hip or femur fracture 
registered in their electronic health records during the study period as described 
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by Requena et al.16 (see ENCEPP registered protocol for the full list of codes14).  
Only the first HF was considered as event for the CCO while for the SCCS all HF 
fractures were considered; however a new fracture was only considered as such 
if at least 12 months had elapsed from the previous HF.  
 
CCO design 
The date of first diagnosis of HF after start of the observation period was 
considered as the index date. For each HF case up to four control moments were 
selected, defined at -91, -182, -273, and -365 days (C1 through C4) prior to index 
date. The selection of control moments included a control moment at one year 
prior to index date to consider potential seasonal variations. Control moments 
were only included if they met all eligibility criteria. In the CCO we adjusted for 
time varying co-medication use in the three months before the index date and 
each control moment by using the same method and algorithm as we did in the 
cohort and NCC design.8 The list of co-medications can be found online in 
Appendix 1 and in the protocol.14 
 
CCO sensitivity analysis 
A prerequisite for CCO is discordancy of the exposure of interest; concordant 
cases, having the same exposure state during all moments, will contribute to the 
estimate of the treatment effect only through the confounding adjustment for co-
medications. When used for the treatment of depression, ADs should be 
prescribed for at least 6 months following symptom resolvement according to 
both British and Dutch guidelines17, 18. To study the effect of such expected low 
discordancy, we included a 1:1 matched analysis of HF-C1, HF-C2, HF-C3, and 
HF-C4 in addition to the 1 to 4 matching of case and control moments. 
 
SCCS design 
The observation time for each individual was divided among the AD exposure 
categories. In the SCCS, age was the only confounder considered and was 
included in the adjusted model as categorical (one year age band for patients 
from 60 to 95 years old, five years age band for other ages) in THIN and as a 
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continuous covariate in Mondriaan (because the age categories were too 
sparsely populated with events). 
 
SCCS sensitivity analyses 
For the SCCS 19 the main assumption is that occurrence of the event must not 
alter the probability of subsequent exposure. This was assessed by defining a 
“pre-exposure” period prior to the first prescription of an antidepressant during 
the study period. Different lengths of the “pre-exposed” were chosen (15, 30, 45, 
and 60-days) and removed from past/non use comparator period to adequately 
cover the period in which the event might have altered the probability of being 
prescribed an AD. 
Another key assumption is that the event should not censor the observation 
period 10; we therefore tested the impact of right censoring at the first event. To 
simulate what happens in real life in a database, where we cannot know how 
many patients are censored at the first event, we varied the proportions of 
subjects to be randomly right censored (0, 2, 5, 10, 20, 50, 100%) and for each 
proportion the IRR was averaged over 1000 replications. 
 
The last planned sensitivity analysis was to facilitate the comparison with the 
traditional designs studying the impact of 6-months free AD prior to their start of 
the observation period to create a ‘new user’ cohort. 
 
Subsequently, as a post-hoc analysis to understand the discrepancy between the 
CCO and SCCS, we investigated the effect of including only patients that had 
discordant exposure in the CCO design. For this purpose the SCCS analysis was 
stratified by subgroups of patients being discordant or concordant in the CCO. 
 
Data analysis 
The association between AD use and HF was assessed comparing ‘current’ and 
‘recent’ use with ‘past/non-use’. In addition, results were stratified by type of AD 
into TCA, SSRI and both. For the CCO, conditional logistic regression was used to 
estimate the OR with 95% confidence intervals (CI). For the SCCS, Poisson 
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regression, with patient identifier and offset for duration included as covariates, 
was used to estimate the incidence rate ratio (IRR) and corresponding 95% CI. 
SAS® 9.3 (SAS Institute, Cary, North Carolina, USA) was used for all statistical 
analyses in THIN and the CCO in Mondriaan; while the SCCS in Mondriaan was 
analysed using R statistical software package version 2.14.2. 
 
Results 
Patient characteristics 
During the study period 9,682 patients in THIN were eligible and characteristics 
of this population are shown in table 1. Patients were on average 77.6 years old 
at the time of HF and almost 79% was female. 
In the CCO, only patients who were discordant for exposure directly contributed 
to the estimate of the treatment effect, consisting of 2,905 patients in THIN. The 
patient characteristics of this discordant subset had on average 14% more co-
morbidities and 15% more co-medications registered per patient than the 
population from which they were extracted and were treated for shorter time 
with ADs in both databases (table 1, Appendix 1). In Mondriaan 277 patients 
were eligible of which 92 were discordant for exposure.  
 
CCO & SCCS main analyses 
In CCO, the OR for current use in THIN, matched by design for age, sex and all 
time-fixed confounders, was 2.45 (95% CI: 2.23-2.69) and adjustment for co-
medication resulted in somewhat lower OR of 2.24 (95% CI: 2.04-2.47) as shown 
in table 2. For current use, in the age-adjusted analysis, the SCCS showed an IRR 
of 1.41 (95% CI 1.32-1.49). In Mondriaan CCO, the OR for current use was 2.93 
(95% CI: 1.75–4.90) and adjusted for comedication 2.57 (95% CI: 1.50-4.43). 
Also in SCCS the age adjusted IRR was lower; 2.14 (95% CI 1.51-3.03). Recent 
use is also associated with increased risk of HF in both case-only designs. 
Figure 2 shows the relative risks of CCO and SCCS for both databases compared 
to other designs.  
 
Type of AD 
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In the CCO design we found higher ORs for HF associated with current SSRI 
exposure compared to TCA (in THIN SSRI: OR 2.89; 95%CI 2.56-3.26, TCA: OR 
1.75 ; 95%CI 1.53-2.02, Table 2 & Figure 3). However, the SCCS resulted in an 
almost equal risk for both AD types in the age-adjusted analysis (in THIN SSRI: 
IRR 1.46; 95%CI 1.35-1.57, TCA: IRR 1.36; 95%CI 1.24-1.50). 
 
To preserve readability of this manuscript and since conclusions are similar, 
sensitivity analyses results are presented only for THIN.  
 
Sensitivity analysis CCO 
The 1:1 comparison of HF to different individual control moments (HF-C1  HF-
C4) resulted in ORs that were similar and did not differ from the 1:4 analysis 
including all control moments in THIN (Figure 4). 
In the HF-C1 comparison, exposure states were largely unchanged between the 
case- and control-moments and discordancy was 15% whereas in the HF-C4 
comparison discordancy increased to 24% (Table 2 in appendix). 
 
Sensitivity analysis SCCS 
Figure 5 and table 3 of the appendix show the results of possible event-exposure 
dependency. Risk of HF during the pre-exposure period was statistically 
significant for pre-exposure period of at least 30 days and increased with the 
length of the pre-exposure period. For instance, for the 30 days pre-exposure 
period IRR was 1.16 and increased to 1.45 for the 60 days pre-exposure period. 
However, the IRR for current users did not seem to be altered by the removal of 
the pre-exposure period from the past/non-use period (varying between 1.40 
and 1.43 in all four scenarios). 
 
When up to 20% of the patients were randomly censored at first event, the IRR 
was still in line with the main analysis, starting diverging when 50% or more of 
the patients were censored (Figure 5, appendix Table 4). When all patients were 
censored at the first event, IRR was considerably higher compared to the main 
analysis. 
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Finally, excluding subjects with an AD prescription in the 6 months before study 
entry did not significantly change the estimates (results not shown). 
 
Post-hoc analysis SCCS 
Including in the SCCS only patients that were discordant in the CCO resulted in 
higher age-adjusted estimates of 4.27 (95%CI 3.87 - 4.70) in THIN. In the 
analysis per AD drug class, the higher risk for SSRI over TCA already observed in 
the other designs seems to exist for discordant patients only (age-adjusted SSRI: 
IRR 4.87; 95%CI 4.33- 5.48 versus TCA: IRR 3.88; 95%CI 3.37-4.47). In the 
subgroup of concordant patients the opposite trends were observed (Table 3). 
However, it is important to realise that all the SCCS results stratified for  
concordancy in CCO are not valid and are presented for illustration only. 
 
Discussion 
Overall observations 
This study shows that application of case-only designs results in risk estimates 
that consistently show an association between both current and recent AD use 
and HF. An elevated risk of HF associated with AD use is in accordance with 
results from other designs that were studied within our PROTECT consortium 
using the same databases.13 
 
1. Comparison of CCO and SCCS 
The CCO risk estimates for current use, matched by design by sex and age, were 
higher in both THIN (74%) and Mondriaan (37%) when compared to the age 
adjusted results from the SCCS study. 
The higher ORs in the CCO could be explained by induction of selection bias 
because in conditional analysis, of all eligible patients in the study, only those 
patients with discordant exposure for AD directly contributed to the estimate of 
the association. In fact, the concordant patients contributed only through the 
effect of the co-medications and this seems quite modest looking at the 
difference between the crude results and the fully adjusted one in the CCO (table 
2). This explanation for the higher ORs in the CCO analysis is supported by the 
results of the SCCS sensitivity analysis where patients with discordant exposure 
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in the CCO showed IRRs much higher than in patients with concordant exposure. 
In the latter group, exposure had a protective effect (table 3).  
 
In the literature, higher risks of HF are reported for SSRI over TCA use when 
cohort and case-control designs are used. 20-22 In this study, the SCCS design 
resulted in similar IRR for SSRI and TCA in the THIN database. This is in line with 
the study by Hubbard et al. who compared a case-control design to a SCCS design 
on CPRD data (UK) and showed that the higher risk of HF in SSRI use over TCA 
use disappeared in the SCCS design.23 Part of their explanation was that 
preferential prescribing of SSRI to frail elderly people to avoid adverse drug 
reactions caused by TCA would induce confounding. By design, these biases are 
eliminated in the case-only designs. However, the CCO in THIN did not show such 
cancellation of the difference between SSRI and TCA in our study. The 
explanation for this is that the selection of only discordant patients in the CCO 
biases the estimates as we observed a higher risk of SSRI over TCA when 
selecting only discordant patients in the SCCS. In fact, estimates in concordant 
patients showed similar risk across SSRI and TCA. 
 
2. Validity of Case-Only designs: analysis of violations of assumptions 
The concept of case-only studies to control by design for time-invariant 
measured and unmeasured confounding sounds attractive. In this discussion we 
will consider the added value of the CCO and SCCS design in studying AD-HF by 
assessing validity, applicability, and resulting estimates. 
 
Validity of CCO design 
The CCO design is susceptible to bias caused by trends in exposure over time.11 
From our descriptive study on AD use in the same databases and study period, 
we know that prevalence of AD use increased less than 4% (THIN) and 0.9% 
(Mondriaan) per year during the study period.6 For THIN this could have 
resulted in an overestimation of the OR by 2% (4%/2) at the most as the 
probability of having a prescription during the four control moments, on average 
a half year before, was slightly lower. 
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A prerequisite of the CCO design is that effects of exposure are transient over 
time and that reference periods or control moments are sufficiently remote in 
time to prevent the long lasting effects of exposure to be present after end of 
exposure (‘carry over effect’). The association between AD and HF is related to 
the increased risk of falling in AD users that is reported to peak about two days 
after dose changes24 and on physiological cumulative and long-lasting effects of 
AD use on bone strength via a decrease in bone mineral density.25 The latter 
might be the reason why in our studies ‘recent use’ was also associated with 
increased risk for HF. These results, therefore, seem to violate the prerequisite 
on transient effect of exposure. 
Exposure needs to be transient to allow discordancy between the case and 
control moments for each patient to contribute to the analysis.26 In addition, to 
prevent non-exchangeability due to selection bias in CCO designs, the chance of 
each exposure state should be independent during the entire observation 
period.27, 28 These assumptions are most likely violated in our study since the 
median treatment duration in our study was 115 days in THIN and 221 in 
Mondriaan and as a result discordancy was low. In the sensitivity analysis where 
the timing of selection of control moments was varied we observed that 
discordancy of exposure dropped in both databases when case and control 
moments were spaced only 3 months in time. 
Finally, not fulfilling the pre-requisite of transient exposure by both prescription 
patterns and methodological choices resulted in the selection of discordant 
patients that seem to be at higher risk compared to ‘stable’ long term users of AD 
as we observed in the post-hoc sensitivity analysis when patients being 
discordant in the CCO were studied in the SCCS design. These patients also 
showed higher co-morbidity and used more co-medication than concordant 
patients. 
Therefore the selction bias we described as possible explanation of the higher 
ORs in the CCO is likely the result of the violation of the assumption of transient 
exposure; if the latter was not (or at least less) violated, the proportion of cases 
with discordant exposure would be greater and the selection bias and its effect 
on the estimate less problematic.  
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Validity of SCCS design 
SCCS can be considered as cohort logic applied to a case-only design, therefore, it 
can be used with non-acute effects of exposure.10 Since this design accounted for 
exposure before and after the HF, it is less susceptible to changes in exposure 
trends over time and it does not require that the exposure is intermittent 
therefore limiting some of the assumptions violation discussed in the CCO.29 
However, SCCS assumes that the event of HF in itself does not alter the 
probability of using AD nor affects censoring of the observation period. We 
assessed the former by including a pre-exposure period in the model; this 
removal of time from past/non-use to the pre-exposure period had little impact 
on the main exposure estimate for current use. Moreover, results show that 
there seem to be a tendency for people who have experienced a HF to be 
prescribed an AD within a relatively short time period and, what is maybe 
surprising, that the effect estimate for the pre-exposure period gets stronger as 
this period expands. 
 
When subjects are censored at their first HF, the assumption underlying the SCCS 
design that events can be recurrent is violated. Weldeselassie et al. 30 and 
Farrington et al. 31 stated that censoring at the event produces a biased estimate 
that is unpredictable in direction. In our study the bias was upward because the 
observation time removed from the analysis was mainly time during which 
subjects were exposed. Morevoer, when censoring at the event, patients with no 
exposure before the event did not contribute to the result other than for the age 
adjustment as they had no contrast in exposure. Results indicated that the bias 
due to censoring at the event was dependent on the magnitude of censoring; if 
less than 20% of patients left or died after the event, the SCCS design still 
produced robust results, though the number of percentage of censoring may 
vary between studies. 
 
3. Comparison of results to cohort and NCC designs 
Case only designs differ from more traditional designs by considering different 
operational hypothesis that are tested within each design. Whereas cohort and 
case control studies answer the questions wheter users have a higher risk 
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compared to non users independent of duration of use, case only studies 
compare changes in exposure within the cases. In the words of Maclure the 
difference can be expressed in answering different questions: ‘Why me?’ versus 
‘Why now?’. 32 
 
In spite of these methodological differences, the SCCS estimates were, except for 
the difference between TCA and SSRI, very similar to the cohort and NCC results 
in both databases. 13  
The higher estimates observed in CCO can be understood by considering that 
chronic users do not directly contribute to the analysis as they are concordant. 
The NCC shares the exclusion of concordant patients from the analysis with the 
CCO; however, for the latter, concordance was based on exposure of the same 
patient; for the former concordance was based on concordant pairs (pairs in 
which the case and control are either both exposed or both not exposed). In our 
analysis CCO concordance could be considered as a proxy for ‘stable patients 
having no need to start or stop their AD medication’; these patients were 
potentially different as we showed in the post-hoc sensitivity analyses, therefore 
excluding them created a selection bias. 
For the NCC, concordance does not have a specific meaning; the likelihood of a 
pair being concordant is unrelated to the clinical exposure pattern of the case 
and therefore less likely to be associated with any important confounder. 
Consequently, concordant patients should not be different and excluding them 
did not bias the NCC results. 
 
Conclusions 
In summary, in accordance with results from the cohort and NCC studies, our 
case only studies confirmed a positive association between AD and HF when, by 
design, all time invariant confounding was adjusted for. 
However, the CCO design is not suited to study this association. The main reason 
seems to be that in both GP databases typical AD exposures were too long. This 
resulted in considerable lack of discordancy which both I) reduced power by 
exclusion of 65-70% of the eligible cases for analysis and II) introduced selection 
bias by selecting patients that needed to change their medication for some 
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reason. Moreover, objective decisions should be made about the timing of 
control moments and these should fit typical exposure of the drug under study 
and the physiological effects of exposure on outcome underlying any association 
studied. 
The SCCS design seems more robust to assumptions about exposure and better 
suited to assess the association between AD and HF. Moreover, similar IRR for 
SSRI and TCA in THIN might show how the SCCS is likely to deal better with the 
problem of confounding by frailty present in the traditional designs. 
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Table 1 – Patient Characteristics of cases in the CCO and SCCS 
 
  THIN Mondriaan 
Demographics/characteristics 
All Cases Discordant 
Cases 
Concordant 
Cases 
All Cases Discordant 
Cases 
Concordant 
Cases 
  N (%) N (%) N (%) N (%) N (%) N (%) 
Patients* 9,682 2,905 6,777 277 92 168 
Age             
Mean 77.6 77.6 77.7 79.2 81.4 78.1 
Std. Dev. 13.4 13.3 13.5 14.6 11.7 15.8 
Sex             
Female 7,608 (78.6) 2,247 (77.3) 5,361 (79.1) 217 (78.3) 70 (76.1) 131 (78.0) 
Male 2,074 (21.4) 658 (22.7) 1,416 (20.9) 60 (21.7) 22 (23.9) 37 (22.0) 
Co-morbidity             
Average Number per Patient 1.20 1.38 1.12 0.98 1.22 0.95 
Co-medication             
Average Number per Patient 1.72 2.02 1.59 2.40 2.72 2.48 
AD Prescriptions             
Average Number per Patient 29.34 22.89 32.11 31.23 20.90 38.01 
Observation period             
Mean (years) 6.6 6.3 6.7 5.5 5.0 5.9 
Median (years) 7.4 6.8 7.7 5.9 4.9 6.2 
Treatment episode             
Mean (days) 323 202 401 458 332 582 
Median (days) 87 70 112 221 191 283 
 
* Number of patients eligible and included in the SCCS. For CCO patients without enough follow-up time before the HF for at least one control 
moment were excluded (350 patients in THIN and 17 in Mondriaan). 
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Table 2. Main analysis Case-Only estimates of the association for AD-HF 
 
CCO THIN Mondriaan 
  
Cases 
Control 
moments 
Crude* 
Comedication 
adjusted 
Cases 
Control 
moments 
Crude* 
Comedication 
adjusted 
  N N OR (95% CI) OR (95% CI) N N OR (95% CI) OR (95% CI) 
Past/non use 
(baseline) 
4,868 20,660 - - 127 567 - - 
Current 4,040 13,506 2.45 (2.23 - 2.69) 2.24 (2.04 - 2.47) 121 368 2.93 (1.75 - 4.90) 2.57 (1.50 - 4.43) 
Recent 424 1,250 2.08 (1.83 - 2.36) 1.95 (1.72 - 2.22) 12 28 3.24 (1.49 - 7.04) 3.22 (1.40 - 7.39) 
SSRI Current 2,155 6,689 3.13 (2.77 - 3.52) 2.89 (2.56 - 3.26) 91 255 4.40 (2.37 - 8.17) 3.80 (1.99 - 7.27) 
TCA Current 1,469 5,120 1.93 (1.68 - 2.21) 1.75 (1.53 - 2.02) 28 101 1.42 (0.62 - 3.22) 1.16 (0.47 - 2.87) 
SSRI and TCA  416 1,697 0.97 (0.70 - 1.33) 0.85 (0.62 - 1.17) 2 12  -  - 
SCCS THIN Mondriaan 
  
Cases Crude* Age adjusted Cases Crude* Age adjusted 
  N PY IRR (95% CI) IRR (95% CI) N PY IRR (95% CI) IRR (95% CI) 
Past/non-use 
(baseline) 
5,278 39,709 - - 132 895 
  
Current 4,379 21,934 1.72 (1.62 - 1.82) 1.41 (1.32 - 1.49) 134 590 2.00 (1.43 - 2.79) 2.14 (1.51 - 3.03) 
Recent 436 2,150 1.52 (1.38 - 1.69) 1.36 (1.22 - 1.50) 11 51 1.50 (0.80 - 2.82) 1.58 (0.84 - 2.96) 
SSRI Current 2,319 10,380 1.91 (1.78 - 2.06) 1.46 (1.35 - 1.57) 94 388 2.57 (1.68 - 3.92) 2.76 (1.75 - 4.35) 
TCA Current 1,505 8,204 1.50 (1.37 - 1.64) 1.36 (1.24 - 1.50) 35 191 1.26 (0.76 - 2.09) 1.35 (0.81 - 2.26) 
SSRI and TCA  555 3,350 1.53 (1.78 - 1.32) 1.25 (1.07 - 1.47) 5 11 - - 
 
*Crude risk estimates in CCO are matched by design for sex and age, in SCCS for sex. 
OR: odds ratio, CI: confidence interval, PY: person years, IRR: incidence rate ratio.  
The sum of cases in CCO and SCCS does not equal because in the CCO only the first fracture is considered and some subjects do not have control moments.  
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Table 3 Sensitivity analyses SCCS in THIN: discordant and concordant patients 
 
 
  THIN 
  Cases Age adjusted Cases Age adjusted 
  N PY IRR (95% CI) N PY IRR (95% CI) 
  Discordant in CCO Concordant in CCO 
Past/non-use 
(baseline) 1,054 11,844 - 4,224 27,865 - 
Current 1,554 5,609 4.27 (3.87 - 4.70) 2,825 16,325 0.68 (0.63 - 0.74) 
Recent 422 933 5.62 (4.99 - 6.34) 14 1,217 0.05 (0.03 - 0.09) 
SSRI Current 932 2,899 4.87 (4.33 - 5.48) 1,387 7,481 0.64 (0.58 - 0.71) 
TCA Current 517 2,062 3.88 (3.37 - 4.47) 988 6,142 0.70 (0.62 - 0.80) 
SSRI and TCA Current 105 648 2.13 (1.60 - 2.84) 450 2,702 0.88 (0.72 - 1.07) 
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Figure captions 
 
Figure 1. Schematic overview of CCO and SCCS design 
 
Figure 2. Risk estimates from CCO and SCCS versus traditional designs 
 
Symbols indicate relative risk estimates, ORs for NCC and CCO, and IRRs for cohort and SCCS, all with 95% CI. 
 
* Comparable models share the same symbols, thus adjustment for age and sex in cohort is compared to age adjusted in SCCS as this is 
already matched on sex by design and to the crude CCO as this is already adjusted on sex and age by design. 
 
Figure 3. Risk estimates by type of AD use 
 
Symbols indicate relative risk estimates, ORs for CCO, and IRRs for SCCS, all with 95% CI. 
 
* Comparable models share the same symbols, thus adjustment for age and sex in cohort is compared to age adjusted in SCCS as this is 
already matched on sex by design. 
 
Figure 4. Sensitivity analysis in CCO: timing control moments  
 
Symbols indicate relative risk estimates, ORs with 95% CI.  
 
Figure 5. Sensitivity analysis in SCCS: pre-exposure periods and right censoring 
  
The left panel shows the relative risk of analysis of a pre-exposure period of different lengths and the influence of this pre-exposure 
period on the relative risk of current use in that analysis. The right panel shows relative risks for current use when different proportions 
of patients are randomly right censored at the event. 
 
* Adjusted model in SCCS is matched on sex by design and adjusted by age. 
